Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Ratio of prostate specific antigen minor molecular forms-to-total prostate specific antigen is constant regardless of the pathological condition of the prostate.

Kobayashi T, Kamoto T, Isogawa Y, Kinoshita H, Terai A, Habuchi T, Ogawa O.

J Urol. 2003 Jan;169(1):121-4. Erratum in: J Urol. 2003 Jul;170(1):194. Kamato, T [corrected to Kamoto, T].

PMID:
12478118
2.

Dose-intensive chemotherapy with syngeneic peripheral blood stem cell support for poor risk germ cell tumor of extragonadal origin: a case report.

Kobayashi T, Yamamoto S, Nakamura E, Kamato T, Kakehi Y, Ogawa O, Ito N, Fukuyama T, Hishizawa M, Ichinohe T.

Jpn J Clin Oncol. 2002 Jan;32(1):33-4.

PMID:
11932361
3.

A novel 5-HT3 receptor agonist, YM-31636, increases gastrointestinal motility without increasing abdominal pain.

Kiso T, Ito H, Miyata K, Kamato T, Naitoh Y, Iwaoka K, Yamaguchi T.

Eur J Pharmacol. 2001 Nov 9;431(1):35-41.

PMID:
11716840
4.

Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro.

Ito H, Kiso T, Miyata K, Kamato T, Yuki H, Akuzawa S, Nagakura Y, Yamano M, Suzuki M, Naitoh Y, Sakai H, Iwaoka K, Yamaguchi T.

Eur J Pharmacol. 2000 Dec 8;409(2):195-201.

PMID:
11104834
5.

Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor.

Nagakura Y, Akuzawa S, Miyata K, Kamato T, Suzuki T, Ito H, Yamaguchi T.

Pharmacol Res. 1999 May;39(5):375-82.

PMID:
10328995
6.
7.

Effects of gastroprokinetic agents on gastroparesis in streptozotocin-induced diabetic rats.

Yamano M, Kamato T, Nagakura Y, Miyata K.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Jul;356(1):145-50.

PMID:
9228202
8.

Effect of a selective 5-HT3 receptor agonist on gastric motility in fasted and fed dogs.

Nagakura Y, Ito H, Kamato T, Nishida A, Miyata K.

Eur J Pharmacol. 1997 May 30;327(2-3):189-93.

PMID:
9200559
9.

Compounds possessing 5-HT3 receptor antagonistic activity inhibit intestinal propulsion in mice.

Nagakura Y, Naitoh Y, Kamato T, Yamano M, Miyata K.

Eur J Pharmacol. 1996 Sep 5;311(1):67-72.

PMID:
8884238
10.

Characterization of 5-hydroxytryptamine (5-HT) receptor subtypes influencing colonic motility in conscious dogs.

Nagakura Y, Kamato T, Nishida A, Ito H, Yamano M, Miyata K.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Apr;353(5):489-98.

PMID:
8740141
13.

Gastrin receptor antagonist YM022 prevents hypersecretion after long-term acid suppression.

Nishida A, Kobayashi-Uchida A, Akuzawa S, Takinami Y, Shishido T, Kamato T, Ito H, Yamano M, Yuki H, Nagakura Y, et al.

Am J Physiol. 1995 Nov;269(5 Pt 1):G699-705.

PMID:
7491961
14.

Species difference in the 5-hydroxytryptamine3 receptor associated with the von Bezold-Jarisch reflex.

Yamano M, Ito H, Kamato T, Miyata K.

Arch Int Pharmacodyn Ther. 1995 Sep-Oct;330(2):177-89.

PMID:
8861711
15.

Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex.

Ito H, Akuzawa S, Tsutsumi R, Kiso T, Kamato T, Nishida A, Yamano M, Miyata K.

Neuropharmacology. 1995 Jun;34(6):631-7.

PMID:
7566499
16.

Gastric mucosal protection by YM638, a novel leukotriene D4 receptor antagonist, in rats.

Miyata K, Kamato T, Nishida A, Takizawa K, Takeda M.

Eur J Pharmacol. 1995 Mar 24;276(1-2):165-75.

PMID:
7781686
17.
18.

Antisecretory and antiulcer effects of YM020, a new H+,K(+)-ATPase inhibitor, in rats and dogs.

Yuki H, Kamato T, Nishida A, Ohta M, Shikama H, Yanagisawa I, Miyata K.

Jpn J Pharmacol. 1995 Jan;67(1):59-67.

19.
20.

Serotonin (5-HT)3-receptor antagonism of 4,5,6,7-tetrahydrobenzimidazole derivatives against 5-HT-induced bradycardia in anesthetized rats.

Yamano M, Kamato T, Nishida A, Ito H, Yuki H, Tsutsumi R, Honda K, Miyata K.

Jpn J Pharmacol. 1994 Jul;65(3):241-8.

21.

Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.

Nishida A, Miyata K, Tsutsumi R, Yuki H, Akuzawa S, Kobayashi A, Kamato T, Ito H, Yamano M, Katuyama Y, et al.

J Pharmacol Exp Ther. 1994 May;269(2):725-31.

PMID:
7910212
22.

Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation.

Miyata K, Ito H, Yamano M, Hidaka K, Kamato T, Nishida A, Yuki H.

Eur J Pharmacol. 1993 Dec 7;250(2):303-10.

PMID:
8112388
23.

Antisecretory effects of a novel and long-lasting histamine H2-receptor antagonist, YM-14471, in rats and dogs.

Yuki H, Kamato T, Nishida A, Fujihara A, Takeda M, Miyata K.

Jpn J Pharmacol. 1993 Nov;63(3):345-51.

24.

Histamine H2-receptor plays only a minor role in histamine-induced wheal response in the squirrel monkey and guinea pig.

Yuki H, Miyata K, Kamato T, Nishida A, Ito H, Takeda M, Honda K.

Jpn J Pharmacol. 1993 Sep;63(1):93-9.

25.

Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets.

Kamato T, Ito H, Nagakura Y, Nishida A, Yuki H, Yamano M, Miyata K.

Eur J Pharmacol. 1993 Jul 20;238(2-3):369-76.

PMID:
8405104
26.

Characterization of YM060, a potent and selective 5-hydroxytryptamine3 receptor antagonist, in rabbit nodose ganglion and N1E-115 neuroblastoma cells.

Ito H, Hidaka K, Miyata K, Kamato T, Nishida A, Honda K.

J Pharmacol Exp Ther. 1992 Dec;263(3):1127-32.

PMID:
1469624
27.

Role of the serotonin3 receptor in stress-induced defecation.

Miyata K, Kamato T, Nishida A, Ito H, Yuki H, Yamano M, Tsutsumi R, Katsuyama Y, Honda K.

J Pharmacol Exp Ther. 1992 Apr;261(1):297-303.

PMID:
1560375
28.

L-365,260, a potent CCK-B/gastrin receptor antagonist, suppresses gastric acid secretion induced by histamine and bethanechol as well as pentagastrin in rats.

Nishida A, Yuki H, Tsutsumi R, Miyata K, Kamato T, Ito H, Yamano M, Honda K.

Jpn J Pharmacol. 1992 Feb;58(2):137-45. Erratum in: Jpn J Pharmacol 1992 Mar;58(3):329.

29.

Serotonin (5-HT)3 receptor blocking activities of YM060, a novel 4,5,6,7-tetrahydrobenzimidazole derivative, and its enantiomer in anesthetized rats.

Miyata K, Kamato T, Yamano M, Nishida A, Ito H, Katsuyama Y, Yuki H, Tsutsumi R, Ohta M, Takeda M, et al.

J Pharmacol Exp Ther. 1991 Nov;259(2):815-9.

PMID:
1941629
30.

Antiemetic effects of YM060, a potent and selective serotonin (5HT)3-receptor antagonist, in ferrets and dogs.

Kamato T, Miyata K, Ito H, Yuki H, Yamano M, Honda K.

Jpn J Pharmacol. 1991 Nov;57(3):387-95.

31.
32.

Studies on the mechanism for the gastric mucosal protection by famotidine in rats.

Miyata K, Kamato T, Nishida A, Honda K.

Jpn J Pharmacol. 1991 Feb;55(2):211-22.

33.

Cardiovascular and bronchial actions of famotidine in anesthetized dogs.

Miyata K, Kamato T, Fujihara A, Takeda M.

Arzneimittelforschung. 1990 Nov;40(11):1234-8.

PMID:
2085336
35.

Characterization of functional properties of C4-binding protein by monoclonal antibodies.

Fujita T, Kamato T, Tamura N.

J Immunol. 1985 May;134(5):3320-4.

PMID:
3872332

Supplemental Content

Loading ...
Support Center